Project Grant R43HL174218
Award Date
9/20/24
Completion Date
9/19/25
Dollars Obligated
$707K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $288,986 to Biotherapeutics, Inc., a biotechnology company in Blacksburg, VA. The grant supports the development of a novel oral immunoregulatory therapeutic for the treatment of asthma. The key objectives are to: 1) Determine the safety profile and pharmacokinetics of the new therapeutic in rats, and 2) Characterize the therapeutic...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $477,191 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to Phrase Health, Inc., a small disadvantaged business located in Philadelphia, PA. The purpose of this 22-month project is to develop a library of "out of the box" quality improvement (QI) templates focused on select lung diseases, including asthma, bronchiolitis, and COPD. The project will involve translating existing QI project templates from...
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, awarded a $310,948 Project Grant to Minnesota Healthsolutions Corporation, a for-profit woman-owned small business, on September 15, 2023. The grant funds the development of an adaptable platform to support patients with behavior change interventions aimed at improving adherence to treatment and prevention for multiple chronic diseases. The platform will utilize remote...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $347,608 to Biotherapeutics, Inc. to develop a novel, oral, once-daily, immunoregulatory therapeutic for the treatment of asthma. The key objectives are to: 1) characterize the therapeutic efficacy and route of administration of the drug candidate in mouse models of asthma, and 2) determine the translational ability of the therapeutic...
The National Heart, Lung, and Blood Institute (NHLBI), under CFDA Program 93.837 Cardiovascular Diseases Research, awarded a $863,328 Project Grant to Aquillius Corp to develop a wearable graphene respiratory sensor for early detection and monitoring of asthma. The sensor is intended to provide real-time continuous monitoring and measurement of pulmonary functions, particularly for children, to improve asthma diagnosis, treatment, and patient care. The Phase I feasibility studies will focus on...
This Project Grant award for $355,935 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837) supports the development of a novel, oral immunoregulatory therapeutic for the treatment of asthma. The primary objectives are to characterize the therapeutic efficacy and dosing regimen of the compound in mouse models of asthma, and to evaluate its ability to modulate immune function and suppress inflammation in human...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $443,544 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to Dasisimulations LLC, a minority-owned small business located in Dublin, Ohio. The grant supports the development and validation of an innovative, AI-driven software platform to automatically perform complex measurements for pre-planning transcatheter aortic valve replacement (TAVR) procedures. The project aims to (1) develop and validate the...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will evaluate the use of mobile devices to extract vital signs to monitor patients with asthma. The $459,127 award to M5 Enterprise, LLC (doing business as Emedical Sentry) aims to improve the detection and management of asthma attacks through remote patient monitoring. The goal is to enhance telehealth by incorporating video-based vital sign...
This $673,581 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to assess disparities in asthma care between Latino and non-Hispanic white adults, and identify the social determinants of health that may underlie these disparities. The grantee, Ochin, Inc., a nonprofit health IT collaborative based in Portland, Oregon, will leverage a large national dataset of electronic health records from...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $604,750 SBIR Phase I project grant (CFDA 93.837 - Cardiovascular Diseases Research) to Scientific Horizons Consulting LLC to develop a novel inhalation device and pulmonary delivery platform for anti-inflammatory agents to manage pain associated with chronic obstructive pulmonary disease (COPD). The project aims to investigate the feasibility of aerosolizing and delivering corticosteroids and non-steroidal anti-inflammatory drugs...